Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $868M | $255M | $159M | $348M | 18.2% | 21.5% | 9.1% |
| 2024 | $715M | $233M | $145M | $219M | 22.1% | 22.8% | 12.9% |
| 2023 | $582M | $222M | $129M | $219M | 27.6% | 32.9% | -29.0% |
| 2022 | $438M | $147M | $181M | $144M | 45.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 437.86 | 582.02 | 714.73 | 868.45 |
| Operating Revenue | - | 437.86 | 582.02 | 714.73 | 868.45 |
| Cost Of Revenue | - | 83.48 | 121.24 | 156.82 | 198.34 |
| Gross Profit | - | 354.37 | 460.79 | 557.92 | 670.11 |
| Operating Expense | - | 234.19 | 268.76 | 367.09 | 461.64 |
| Research And Development | - | 70.89 | 76.06 | 145.82 | 189.59 |
| Selling General And Administration | - | 163.30 | 192.69 | 221.27 | 272.05 |
| Total Expenses | - | 317.67 | 389.99 | 523.91 | 659.98 |
| Operating Income | - | 120.19 | 192.03 | 190.83 | 208.47 |
| Total Operating Income As Reported | - | 120.19 | 192.03 | 190.83 | 208.47 |
| EBITDA | - | 146.87 | 221.51 | 233.41 | 255.05 |
| Normalized EBITDA | - | 146.87 | 231.28 | 233.41 | 255.05 |
| EBIT | - | 123.48 | 197.15 | 209.30 | 229.71 |
| Interest Income | - | 3.13 | 14.73 | 18.54 | 21.92 |
| Interest Expense | - | 18.80 | 23.76 | 17.50 | 14.65 |
| Net Interest Income | - | -15.67 | -9.03 | 1.05 | 7.28 |
| Other Non Operating Income Expenses | - | 0.17 | 0.16 | -0.07 | -0.68 |
| Other Income Expense | - | 0.17 | -9.61 | -0.07 | -0.68 |
| Interest Income Non Operating | - | 3.13 | 14.73 | 18.54 | 21.92 |
| Interest Expense Non Operating | - | 18.80 | 23.76 | 17.50 | 14.65 |
| Net Non Operating Interest Income Expense | - | -15.67 | -9.03 | 1.05 | 7.28 |
| Pretax Income | - | 104.69 | 173.40 | 191.80 | 215.06 |
| Tax Provision | - | -76.78 | 44.54 | 46.31 | 56.38 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -2.51 | 0 | 0 |
| Net Income Continuous Operations | - | 181.47 | 128.85 | 145.49 | 158.69 |
| Net Income From Continuing And Discontinued Operation | - | 181.47 | 128.85 | 145.49 | 158.69 |
| Net Income From Continuing Operation Net Minority Interest | - | 181.47 | 128.85 | 145.49 | 158.69 |
| Net Income | - | 181.47 | 128.85 | 145.49 | 158.69 |
| Net Income Common Stockholders | - | 181.47 | 128.85 | 145.49 | 158.69 |
| Net Income Including Noncontrolling Interests | - | 181.47 | 128.85 | 145.49 | 158.69 |
| Normalized Income | - | 181.47 | 136.11 | 145.49 | 158.69 |
| Diluted NI Availto Com Stockholders | - | 181.47 | 128.85 | 145.49 | 158.69 |
| Basic Average Shares | - | 59.17 | 59.47 | 56.89 | 57.49 |
| Diluted Average Shares | - | 61.10 | 60.37 | 57.87 | 58.54 |
| Reconciled Depreciation | - | 23.38 | 24.36 | 24.11 | 25.34 |
| Reconciled Cost Of Revenue | - | 83.48 | 121.24 | 156.82 | 198.34 |
| Total Unusual Items | - | 0 | -9.77 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | -9.77 | 0 | 0 |
| Special Income Charges | - | 0 | -9.77 | 0 | 0 |
| Other Special Charges | 26.15 | - | 9.77 | - | - |
| General And Administrative Expense | - | 84.02 | 95.29 | 110.35 | 152.54 |
| Other Gand A | - | 84.02 | 95.29 | 110.35 | 152.54 |
| Selling And Marketing Expense | - | 79.28 | 97.40 | 110.92 | 119.51 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc.this co. | HRMY | $1.9B | 12.02 | 2.19 | 18.2% | 5.17 |
| Trevi Therapeutics, Inc. | TRVI | $2.0B | -46.25 | 10.79 | -23.3% | -45.92 |
| Iovance Biotherapeutics, Inc. | IOVA | $2.0B | -5.00 | 2.80 | -56.0% | -5.25 |
| Ocular Therapeutix, Inc. | OCUL | $1.9B | -7.25 | 2.94 | -40.6% | -5.07 |
| Astrana Health, Inc. |
| 2021 | - | - | - | - | - | - | - |
| ASTH |
| $1.9B |
| 83.46 |
| 2.41 |
| 2.9% |
| 18.67 |
| Stoke Therapeutics, Inc. | STOK | $1.9B | -272.47 | 5.32 | -2.0% | -95.36 |
| Pulse Biosciences, Inc. | PLSE | $1.9B | -25.62 | 23.12 | -90.2% | -23.61 |
| Zymeworks Inc. | ZYME | $1.8B | -22.76 | 6.88 | -30.2% | -22.40 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B | -14.08 | 8.67 | -61.6% | -13.48 |
| Peer Median | - | -18.42 | 6.10 | -35.4% | -17.94 | |
Historically, Nov has averaged the highest return (+10.4%); Feb the lowest (-6.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.4%Negative MonthJan 2026: -2.41% | -21.9%Negative MonthFeb 2026: -21.85% | -1.9%Neutral MonthMar 2026: -1.86% | +11.6%Positive MonthApr 2026: +11.60% | +1.1%Neutral MonthMay 2026: +1.06% | +15.3%Positive MonthJun 2026: +15.26% | -3.2%Negative MonthJul 2026: -3.21% | +13.3%*Positive MonthAug 2026: +13.31% | — | — | — | — |
| 2025 | +12.7%Positive MonthJan 2025: +12.67% | -12.7%Negative MonthFeb 2025: -12.69% | -1.9%Neutral MonthMar 2025: -1.95% | -11.2%Negative MonthApr 2025: -11.21% | +17.1%Positive MonthMay 2025: +17.07% | -8.4%Negative MonthJun 2025: -8.41% | +11.3%Positive MonthJul 2025: +11.33% | +4.9%Positive MonthAug 2025: +4.86% | -25.3%Negative MonthSep 2025: -25.29% | +3.7%Positive MonthOct 2025: +3.66% | +23.5%Positive MonthNov 2025: +23.52% | +6.0%Positive MonthDec 2025: +6.04% |
| 2024 | -2.4%Negative MonthJan 2024: -2.35% | +1.8%Neutral MonthFeb 2024: +1.78% | +4.6%Positive MonthMar 2024: +4.61% | -8.0%Negative MonthApr 2024: -7.95% | -4.9%Negative MonthMay 2024: -4.89% | +2.6%Positive MonthJun 2024: +2.62% | +12.2%Positive MonthJul 2024: +12.23% | +6.3%Positive MonthAug 2024: +6.26% | +11.2%Positive MonthSep 2024: +11.17% | -19.7%Negative MonthOct 2024: -19.67% | +7.9%Positive MonthNov 2024: +7.91% | -0.7%Neutral MonthDec 2024: -0.75% |
| 2023 | -12.6%Negative MonthJan 2023: -12.58% | -8.6%Negative MonthFeb 2023: -8.59% | -25.8%Negative MonthMar 2023: -25.85% | -1.3%Neutral MonthApr 2023: -1.26% | +7.3%Positive MonthMay 2023: +7.26% | +1.8%Neutral MonthJun 2023: +1.76% | +0.5%Neutral MonthJul 2023: +0.51% | +2.5%Positive MonthAug 2023: +2.49% | -9.6%Negative MonthSep 2023: -9.60% | -28.2%Negative MonthOct 2023: -28.17% | +23.4%Positive MonthNov 2023: +23.45% | +11.1%Positive MonthDec 2023: +11.15% |
| 2022 | -15.9%Negative MonthJan 2022: -15.90% | +11.4%Positive MonthFeb 2022: +11.43% | +21.7%Positive MonthMar 2022: +21.75% | -7.4%Negative MonthApr 2022: -7.42% | -3.2%Negative MonthMay 2022: -3.20% | +11.9%Positive MonthJun 2022: +11.86% | +4.0%Positive MonthJul 2022: +4.02% | -13.4%Negative MonthAug 2022: -13.44% | +0.9%Neutral MonthSep 2022: +0.87% | +17.4%Positive MonthOct 2022: +17.41% | +14.9%Positive MonthNov 2022: +14.94% | -7.8%Negative MonthDec 2022: -7.81% |
| 2021 | — | — | — | — | +9.1%Positive MonthMay 2021: +9.08% | -11.7%Negative MonthJun 2021: -11.67% | -7.3%Negative MonthJul 2021: -7.33% | +29.5%Positive MonthAug 2021: +29.55% | +13.1%Positive MonthSep 2021: +13.10% | +8.2%Positive MonthOct 2021: +8.19% | -17.8%Negative MonthNov 2021: -17.80% | +25.1%Positive MonthDec 2021: +25.08% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
